Evidence map›Paper›PMID 22684017›Full record

ReviewNanomedicine : nanotechnology, biology, and medicine2013

The big picture on nanomedicine: the state of investigational and approved nanomedicine products.

Michael L Etheridge, Stephen A Campbell, Arthur G Erdman, Christy L Haynes, Susan M Wolf, Jeffrey McCullough

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine : nanotechnology, biology, and medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 262 papers.

0numbers the graph read from it
0cells of the map it votes in
262citing papers in PubMed
34.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

262 citing papers in PubMed, 1,024 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Intraorgan and targeted nanodelivery in organ transplantation of nonhuman primates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. From Nanoparticle Design to Clinical Translation in Cancer Therapy.International journal of molecular sciences · 2026
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

202 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Michael L EtheridgeDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.
Stephen A Campbell
Arthur G Erdman
Christy L Haynes
Susan M Wolf
Jeffrey McCullough
University of Minnesota · US

Funding

Nanodiagnostics and Nanotherapeutics: Building Research Ethics and OversightRC1HG005338 · NHGRI · UNIVERSITY OF MINNESOTA · PI WOLF, SUSAN M. · 2009 to 2010
$914k
NHGRI NIH HHS 1-RC1-HG005338-01NHGRI NIH HHS RC1 HG005338
6 · The paper itself

Abstract

Developments in nanomedicine are expected to provide solutions to many of modern medicine's unsolved problems, so it is no surprise that the literature contains many articles discussing the subject. However, existing reviews tend to focus on specific sectors of nanomedicine or to take a very forward-looking stance and fail to provide a complete perspective on the current landscape. This article provides a more comprehensive and contemporary inventory of nanomedicine products. A keyword search of literature, clinical trial registries, and the Web yielded 247 nanomedicine products that are approved or in various stages of clinical study. Specific information on each was gathered, so the overall field could be described based on various dimensions, including FDA classification, approval status, nanoscale size, treated condition, nanostructure, and others. In addition to documenting the many nanomedicine products already in use in humans, this study identifies several interesting trends forecasting the future of nanomedicine. FROM THE CLINICAL EDITOR: In this one of a kind review, the state of nanomedicine commercialization is discussed, concentrating only on nanomedicine-based developments and products that are either in clinical trials or have already been approved for use.

Indexed as

NanomedicineUnited StatesUnited States Food and Drug Administration

Identifiers

PMID22684017
PMCPMC4467093
OpenAlexW1972180606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.